Sandra A. Milligan, MD, JD, currently serves as Senior Vice President and Head of Global Regulatory Affairs and Clinical Safety of Merck, consisting of the global Regulatory, Safety and CMC functions of Merck Research Laboratories. She previously served as Vice President, Global Regulatory, Immunology, Respiratory, Infectious Diseases and Ophthalmology for Genentech/Roche where she developed and directed global strategic regulatory plans to facilitate and optimize product development, regulatory approval, and commercialization. Previous to Genentech/Roche she served at Amgen for almost 10 years in various roles, including Global Regulatory Therapeutic Area Head for the Bone franchise, as Head of Regulatory Communications Strategy & Operations, and as Senior Counsel for the Development, Regulatory & Compliance Law Group, where she provided strategy for development, regulatory and safety groups. In addition to serving on the DIA Board of Directors and current President-Elect, Sandra has served as the Program Chair for the DIA 2013 Annual Meeting in Boston, as well as co-chair of the Public Policy/Health Care Compliance/Regulatory Law Annual Meeting track. Sandra is a graduate of The George Washington University School of Medicine and the Georgetown University Law Center and attended UC Irvine for undergraduate studies.